Symbols

ZVRA

Zevra·NASDAQ

--(--)

ZVRA fundamentals

ZVRA Q4 2025 Earnings

Zevra (ZVRA) released its earnings on Mar 9, 2026: revenue was 34.10M (YoY +184.17%), beat estimates; EPS was 0.19 (YoY +128.36%), beat estimates.

Revenue / YoY

34.10M

+184.17%

EPS / YoY

0.19

+128.36%

Report date

Mar 9, 2026

ZVRA Earnings Call Summary for Q4,2025

Revenue Surge: 2025 net revenue of $106.5 million, with MIPLYFFA driving 82% of sales. Q4 2025 revenue up 15% YoY.
Patient Growth: 52 new enrollment forms in 2025, 24 in Q4, with 50% adults on therapy. Global EAP expanded to 113 patients.
Pipeline Momentum: Celiprolol Phase III study 35% enrolled; FDA engagement for accelerated development. EMA MAA response due Q2 2026.
Financial Strength: $238.9 million cash; net income of $83.2 million for 2025, reversing prior year loss.

Earnings

EPS

Revenue

Revenue & Expenses

ZVRA has released its 2025 Q4 earnings report, with revenue of 34.13M, reflecting a YoY change of 183.36%, and net profit of 12.16M, showing a YoY change of 134.04%. The Sankey diagram below clearly presents ZVRA's revenue sources and cost distribution.

Key Indicators

Zevra (ZVRA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Zevra (ZVRA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Zevra (ZVRA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Zevra (ZVRA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown